Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and Female outpatients 18-65 years of age
Eligible subjects from Trials 331-10-227, 331-10-228 or 331-12-282:
Subjects who completed participation in the Double-blind Randomization Phase (i.e. Week 14 visit) in Trial 331-10-227, Trial 331-10-228, or Trial 331-12-282 or
Subjects who met criteria for a response, but did not meet criteria for remission at Week 14 of either trial
Eligible subjects from other Phase 3, Double-blind, Brexpiprazole MDD trials:
Subjects who completed the last scheduled visit of the prior Double-blind Randomized Phase 3 trial.
You may not be if
Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving OPC-34712.
Subjects with a major protocol violation during the course of their participation in the Double-blind Randomization Phase
Clareo Health | Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
